Register now
To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.
Already have an account?
If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.
The type and intensity of undesirable effects are similar between SYMBICORT TURBUHALER and its components, budesonide and formoterol.No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds.
The most common drug related adverse reactions are pharmacologically predictable side-effects of beta2-agonist therapy, such as headaches, tremor, palpitations, and coughing, which tend to be mild and disappear within a few days of treatment.
The type and intensity of undesirable effects are similar between SYMBICORT TURBUHALER and its components, budesonide and formoterol.No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds.
The most common drug related adverse reactions are pharmacologically predictable side-effects of beta2-agonist therapy, such as headaches, tremor, palpitations, and coughing, which tend to be mild and disappear within a few days of treatment.
Please see the Product Monograph for more information on adverse reactions.
COPD: chronic obstructive pulmonary disease.
Reference:
SYMBICORT® and TURBUHALER® are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
